UK and Australia clear Ranbaxy’s Paonta Sahib plant

Regulators in the UK and Australia have issued GMP certificates for Ranbaxy Laboratories' Paonta Sahib plant after a joint inspection deemed manufacturing practices were up to code.

The accreditation, which followed a routine re-audit in November, is the first positive news for the plant since the US Food and Drug Administration (FDA) imposed an import ban and halted its review of all drugs made there earlier this year.

While the Therapeutic Goods Administration (TGA) approval is limited to the sale of drugs in Australia, clearance from the Medicines and Healthcare products Regulatory agency (MHRA) enables Ranbaxy to sell medicines in both the UK and Europe under the regions mutual recognition procedure.

Related Topics

GlobalizationMarkets & regulatory newsQA/QC

Related news

US approvals provide some respite for Ranbaxy

Two approvals in a week for drugs made at Ranbaxy’s New Jersey OHM Laboratories subsidiary have eased the generics firm’s North American regulatory woes and strengthened its position in the expanding US market.

“Untrue data” from Ranbaxy plant news to Daiichi

 Daiichi Sankyo, the Japanese drug firm that bought a controlling stake in India’s Ranbaxy last year, says it had no knowledge of FDA concerns that led to a block on ANDA reviews for drugs made at the latter’s Paonta Sahib facility.

Ranbaxy made “untrue” statement in filings says FDA

Ranbaxy’s problems with the US FDA were ratcheted up a notch yesterday when the agency halted its review of products made at the firm’s plant in Paonta Sahib, India after uncovering “untrue statements” in ANDA’s and NDA filings.